Embla Medical hf (OCSE:EMBLA) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:EMBLA Embla Medical hf OCSE:EMBLA
91 GF Score
Price kr26.40
GF Value kr34.62
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Embla Medical hf Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Embla Medical hf Valuation Rank Related Terms

OCSE:EMBLA
91GF Score
Embla Medical hf OCSE:EMBLA
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Embla Medical hf (OCSE:EMBLA) Overvalued in 2026?

Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued. The current stock price of kr26.40 is trading 23.7% below its estimated GF Value™ of kr34.62. GuruFocus considers Embla Medical hf to be Modestly Undervalued.

Key valuation signals for OCSE:EMBLA:

  • Valuation Rank:
  • GF Value™: kr34.62 vs. price of kr26.40 (23.7% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the OCSE:EMBLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Embla Medical hf Business Description

Other Exchanges 0FIW:UK5IQ:Germany
Address Grjothals 5, Reykjavik, ISL
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
91GF Score

Get the complete analysis for OCSE:EMBLA

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr26.40
Price
kr34.62
GF Value